TY - JOUR
T1 - A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer
AU - Horn, Leora
AU - Zhao, Zhiguo
AU - Sandler, Alan
AU - Johnson, David
AU - Shyr, Yu
AU - Wolff, Steven
AU - Devore, Russell F.
AU - Laskin, Janessa
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Objectives: Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings. Methods: Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function were eligible. Patients were treated with carboplatin AUC 5 intravenously over 30-60 minutes on day 1, followed by CPT-11(irinotecan) 50 mg/m2 intravenously over 30-90 minutes on days 1 and 8 every 3 weeks for 4-6 cycles at the discretion of the treating physician. Results: Fifty-six patients were enrolled, and 50 patients were eligible. The median age of patients was 60.1 years. The most common toxicities were neutropenia, thrombocytopenia, nausea/vomiting, and dehydration. The overall response rate was 58%. Median PFS was 5.3 months, median overall survival was 9.7 months, and 1-year overall survival was 28.7%. Conclusions: Carboplatin and irinotecan is a safe and reasonable combination for the treatment of patients with ED-SCLC.
AB - Objectives: Our study set out to determine the antitumor efficacy of carboplatin and irinotecan as assessed by response rate in persons with chemotherapy-naive extensive-disease, small-cell lung cancer (ED-SCLC). Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings. Methods: Patients with previously untreated ED-SCLC, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2, life expectancy ≥ 3 months, and adequate organ function were eligible. Patients were treated with carboplatin AUC 5 intravenously over 30-60 minutes on day 1, followed by CPT-11(irinotecan) 50 mg/m2 intravenously over 30-90 minutes on days 1 and 8 every 3 weeks for 4-6 cycles at the discretion of the treating physician. Results: Fifty-six patients were enrolled, and 50 patients were eligible. The median age of patients was 60.1 years. The most common toxicities were neutropenia, thrombocytopenia, nausea/vomiting, and dehydration. The overall response rate was 58%. Median PFS was 5.3 months, median overall survival was 9.7 months, and 1-year overall survival was 28.7%. Conclusions: Carboplatin and irinotecan is a safe and reasonable combination for the treatment of patients with ED-SCLC.
UR - http://www.scopus.com/inward/record.url?scp=79959601531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959601531&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2011.03.013
DO - 10.1016/j.cllc.2011.03.013
M3 - Article
C2 - 21663858
AN - SCOPUS:79959601531
SN - 1525-7304
VL - 12
SP - 161
EP - 165
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 3
ER -
